May 1, 1992

In search of predictive markers of remission from insulin dependence in type 1 diabetes: a preliminary report

Diabetes Research and Clinical Practice
E GuastamacchiaG M Nardelli

Abstract

We studied 18 newly diagnosed diabetic patients (8 males and 10 females, aged 18-26 years, within 10-120 days from the onset of symptoms) who were submitted for 15 days to intensive insulin therapy performed via subcutaneous insulin infusion (CSII). We investigated some metabolic and immunological parameters in order to identify a possible marker to predict the selection of patients potentially more responsive to CSII treatment for the remission of type 1 diabetes. In accordance with the International Diabetes Immunology Group we considered clinical remission as being the withdrawal of insulin therapy for at least 3 months. In order to assess beta-cell function a fasting and post-prandial serum C-peptide, blood glucose and HbA1c were performed on all patients before, and 3 days after, the discontinuation of CSII. Islet cell antibodies were determined in all sera by indirect immunofluorescence. Analysis of T-lymphocyte subpopulations was carried out before starting the therapy. The following monoclonal antibodies were used: CD4, CD8, CD57, CD25, HLA-DR. The levels of C3 and C4 and serum IgG, IgA and IgM were also evaluated. After CSII, 11 of 18 patients showed remission. At the beginning of the study we observed no major differe...Continue Reading

Mentioned in this Paper

Glycated Hemoglobin TEST
Metabolic Process, Cellular
Monoclonal Antibodies
Monoclonal antibodies, antineoplastic
T-Lymphocyte
Remission, Spontaneous
Leukocyte Differentiation Antigens, Human
Implantable Programmable Insulin Pump
Interleukin 2 Receptor, Alpha
C-Peptide

About this Paper

Related Feeds

Autoimmune Diabetes & Tolerance

Patients with type I diabetes lack insulin-producing beta cells due to the loss of immunological tolerance and autoimmune disease. Discover the latest research on targeting tolerance to prevent diabetes.